Cell Line Development Services - Abzena

Mammalian Cell Line Development

Rapidly progress therapeutic antibody & recombinant vaccine programs from DNA to RCB with our enhanced, mammalian cell line development (CLD) offering - AbZelectPRO™, AbZelectPRO™-KO, and AbZelectPRO™-KO+.

Watch Video Cell Line Development Info Sheet

Achieve more from your cell line with our robust & flexible standalone or fully integrated AbZelectPRO™ platforms

CLD Services - Higher Productivity

Higher Productivity

High-quality mAb titers up to 10g/L

CLD Services - Proven Performance

Proven Performance

>90 INDs & 4 marketed drugs with Revvity GS KO & >20 INDs with 2G UNic® Vector

CLD Services - Rapid Timelines

Rapid
Timelines

Go from DNA to RCB in 10 weeks

CLD Services - No Extra Fees

No Extra
Fees

No Royalty Fees & No Exit Fees

At Abzena, we understand the importance of optimal mammalian cell line development (CLD). That’s why we partnered with industry leading firms, like Revvity and ProteoNic Biosciences, to offer our customers the most robust & flexible platform options for their complex biologics and bioconjugates with AbZelectPRO™, AbZelectPRO™-KO and AbZelectPRO™-KO+.

Discover a new standard of excellence in stable cell line development services.

  • Standalone and integrated CLD models available with transparent pricing to IND with no royalty fees & no exit fees.
  • CLD Services - Revvity’s CHOSOURCE™ GS Knockout Cell Line - Abzena
    Revvity’s CHOSOURCE™ Glutamine Synthetase (GS) knockout cell line is a well-established, cGMP-manufactured CHO-K1-derived suspension cell line.
  • CLD Services - ProteoNic’s 2G UNic Vector - Abzena
    ProteoNic’s 2G UNic® vector boosts CHO cell protein yields by enhancing transcription, translation, and stability – enabling high titers and rapid cell line development.
Contact Us

Enhanced Cell Line Development Platforms

AbZelectPRO™: Enhanced Cell Line Platform - Abzena

Discover AbZelectPRO™

AbZelectPRO™-KO: Robust GS Knockout Cell Line Platform - Abzena

Discover AbZelectPRO™-KO

Specialized Platform for Afucosylated Proteins

AbZelectPRO™-KO+: Advanced GS Knockout ADCC+ CLD Platform - Abzena

AbZelectPRO™-KO+: The Advanced GS Knockout ADCC+ CLD Platform

  • Revvity’s CHOSOURCE™ ADCC+ cell line is a double knockout of both the glutamine synthetase (GS) & fucosyltransferase genes
  • Enables the production of fully afucosylated proteins on a traditional GS background

Why afucosylated antibodies?
Elimination of the fucose in the Fc glycan structure is known to enhance Antibody Dependent Cellular Cytotoxicity (ADCC) activity of NK effector cells by increasing binding to the FcγRIIIa (CD16a) receptor.

  • Increases therapeutic efficacy of antibodies, particularly in oncology, anti-infectious & anti-inflammatory conditions
  • Increase in drug potency, expanding therapeutic window & reducing dosage requirements
  • Potentially reduces undesirable side effects & broadens patient population
Discover AbZelectPRO™-KO+

Extensive Expertise & Capabilities

With over 20 years of experience and a commitment to quality excellence, our dedicated CLD team has developed hundreds of cell lines that have rapidly progressed from IND through to clinical trials.

Our mammalian cell line development offering includes:

  • Extensive expertise & flexibility to apply our processes to other proprietary host cell lines, including: CHOSOURCE™ (GS Knockout), CHOSOURCE™ ADCC+ (GS Knockout), CHO-K1, CHO-ZN, CHO BIOP3
  • Diverse formats expressed – mAbs, Fabs, BsABs, fusion proteins, biosimilars, vaccines, nanoparticles, etc.
  • Regulatory track record – >90 INDs & 4 marketed drugs with CHOSOURCE™ cell lines & >20 INDs with 2G UNic® vector
  • Stability – Sustained productivity up to 60 generations
  • Rapid timelines – DNA to Research Cell Banks in 10 weeks and 18 weeks for Master Cell Banking
  • Next-gen vector technology – ProteoNic’s 2G UNic vector offers increased titer with exceptional clone stability
  • Higher product yield – expression of IgG titre up to 10g/L
  • Quality – Reproducible PQA at all stages, full traceability, compliant with ICH-Q5
  • Robust scalable process – up to 2,000L
  • In-house state-of-the-art analytics – stage-appropriate, fit-for-purpose assessments and technologies
  • Fast stable pool material generation – stand-alone gram-scale material supply for early process, analytical, formulation, or tox studies up to 12L.
  • Fully integrated CLD programs – from transfection and cloning through stability and GMP manufacture.

Latest Cell Line Development Info Sheet

Abzena's Robust-Flexible AbZelectPRO Cell Line Platforms Info Sheet - Abzena

Each CLD project is tailored to your needs and handled by a dedicated team that works with you from project kick-off to completion. Whether you’re in need of fast stable pool material to generate data or a fully integrated CLD program, our team works with you to get an in-depth understanding of your molecule to determine the best strategy to reduce timelines without compromising quality.

Find out how our newly enhanced CLD solution provides the foundation of biopharmaceutical development success by downloading our new info sheet.

New Info Sheet Discover AbZelectPRO™

Our Approach to Mammalian Cell Line Development

AbZelectPRO™: Enhanced Cell Line Development - Abzena

Our unique standalone or fully integrated CLD approach encompasses three key steps to ensure a robust and scalable cell line:

  • ​Optimize construct & vector design at the start​
  • Leverage comprehensive analytical capabilities to rapidly characterize molecules​
  • Ensure only clones with desired attributes advance through CLD process
Contact Us

Our Cell Line Development Workflow

Cell Line Development Workflow - Abzena

Material Generation Using Fast Stable Pools

Having high quality material is essential to generate data you can trust in early development. At Abzena, we have a variety of options for generating material that are stage-appropriate from mg to gram scale for fast stable pools to remove activities off the CLD critical path. Our experts in downstream bioprocessing laboratory are well equipped to provide up to 10g of non-GMP shake-flask material that can either support:

  • Stand-alone material supply for mAb or bioconjugation programs
  • Non-GMP material supply for activities including:
    • Early downstream process development and DoE using PreDictor plates
    • Analytical method development
    • Preliminary stability studies
    • Formulation development
    • In vivo studies – including early dose- ranging and non-GLP toxicology

Key elements include:

  • Gram- scale production in as little as 7 weeks
  • Not limited to mAbs, able to produce material for bispecifics, fusion proteins, non-mAbs
  • Platform processes for swift progression through process development
  • Rapid development of high-quality clones for manufacturing
  • Utilization of widely available chemically defined commercial media and feeds for easier transfer

Success in CLD Starts with Effective Analytics

Stage-appropriate, fit-for-purpose assessments & technologies provide in-house analytical solutions.

Abzena offers state-of-the art analytical capabilities to support CLD. We understand that analytical methods are essential to all aspects of pre-clinical drug development, informing critical decisions and de-risking subsequent development phases. For CLD, we use advanced screening assays to identify and select top-performing clones for robust protein expression.

This includes measuring product titers, evaluating growth characteristics, and performing early-stage quality checks – such as glycosylation profiling or charge heterogeneity – to ensure each clone meets specific project goals based on the target product profile (TPP).

Key in-house capabilities include:

  • Robust Characterization
  • Developability Assessments
  • Mass-Spec Capabilities
  • Formulation Development
Discover Analytical Method Development

Fully Integrated Support from CLD through to IND

Cell Line Development Approach - Abzena

What sets our mammalian cell line development services and solutions apart?

  • We offer standalone or fully integrated cell line development workflows that shorten timelines to IND enabling material, supported by using fast stable pools to generate early-stage material for characterization, pre-formulation, analytics and lead molecule selection.
  • For complex biologic programs, we deliver increased productivity through our AbZelectPRO™, AbZelectPRO™-KO and AbZelectPRO™-KO+ platforms, which combines either our host CHO-K1 cell line or Revvity’s CHOSOURCE™ with ProteoNic’s premium expression vector technology 2G UNic®.
  • Applying our technologies and experience in proteomics, protein engineering, bioconjugation and formulation development, we design novel subunit and conjugate vaccine candidates.
  • We have the flexibility and expertise to apply our processes to other proprietary host cell lines.
  • Transparent pricing which includes ProteoNic and Revvity fees to IND.
  • No royalty and no exit fees, portable to wherever you want to go.
Contact Us

ProteoNic’s 2G UNic® Vector Technology

  • Combines optimized proprietary genetic elements in one vector
  • Double promoters drive higher rates of transcription
  • Optimized UTRs stabilize mRNA and enhance ribosome binding
  • Epigenetic stabilization for greater stability and reduced gene silencing
  • Over 20 IND filings using 2G UNic®

Benefits

  • Stable pools expressing 3-4g/L in 4 weeks
  • Clones expressing up to 10g/L in 10 weeks
  • Clone stability to over 60 generations
Learn more about ProteoNic

Discover AbZelectPRO™

About AbZelectPRO™ CLD Platform

Move your cell line development efficiency forwards with our AbZelectPRO™ platform.

Learn More

Latest AbZelectPRO™ Info Sheet

AbZelectPRO™-KO & AbZelectPRO™-KO+, new CHOSOURCE™ GS knockout platforms are available as a standalone CLD offering or as a fully integrated GMP program.

Learn More

Enhanced AbZelectPRO™ News

Enhancing our AbZelectPRO™ mammalian cell line development offering with two new GS knockout platforms including double GS knockout with ADCC+.

Learn More

Related Services

Biosimilar Cell Line Development

We help you maintain biosimilarity, critical for the regulatory approval of biosimilar products, by developing your cell line using the originator cell type.

Learn More

Cell Line Characterization

The safety and quality of your biologic product starts with the right cell line, discover our GMP-compliant cell line characterization methods.

Learn More

Research Cell Banking (RCB)

From transfection pools or non-clonal cell lines we apply our robust single cell cloning process to rapidly isolate and identify the most productive monoclonal populations.

Learn More

Vaccine Development

Applying our solutions and experience in proteomics, protein engineering, bioconjugation and formulation development, we design novel subunit and conjugate vaccine candidates.

Learn More

Analytical Development

Your product development program will be accelerated by leveraging our expansive in-house capabilities, technologies, and knowledge to deliver methods tailored to your molecule of interest.

Learn More

Process Development

We use our knowledge of cGMP manufacturing to transfer or develop the most effective processes for manufacturing at toxicology, clinical, and commercial scale.

Learn More